WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST Last year was a curious one in the world of biopharma CEO compensation, as several high-profile chiefs made for the exit—some as part of routine transitions, while other departures have presaged larger problems, including at home and at the company. And as has been the case for many years, 2021's top-paid execs were exclusively men, but female biopharma leaders have been gaining on the pack in recent months. The full list, plus our top stories of the week, follow below. | |
|
Featured Story | By Eric Sagonowsky For months, Novartis has hinted at layoffs coming for some of its global staff. Now, the news has come down from HQ. read more |
| |
|---|
|
Top Stories Of The Week By Annalee Armstrong While Galapagos is stocking its pipeline by way of two acquisitions, the biotech is also cleaning house, sending the rights for a respiratory disease drug back to Molecure. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In a year in which biopharma revenues increased dramatically, especially among companies that brought COVID-19 products to the market, many firms laid out eye-popping pay packages for their chief executives. Bookending this year's list are longtime CEOs who retired from powerhouse U.S. companies during the year—No. 1 Alex Gorsky of Johnson & Johnson and No. 15 Ken Frazier of Merck. read more By Max Bayer Arch Venture Partners has raised nearly $3 billion in a new venture fund, a glimmer of hope as biotechs large and small lick their wounds amid a market downturn that's lasted more than a year. The early investment firm was able to secure roughly a billion more dollars this time around compared to its previous fund. read more By Angus Liu The future of BioMarin’s first-of-its-kind hemophilia gene therapy remains uncertain at the FDA, but its EU regulatory path now looks clearer. Despite questions about the one-time drug's long-term efficacy, the EMA has recommended a conditional nod. read more By Annalee Armstrong Deal values are down by 58% and volume has decreased by 33%, but fear not, the pharmaceutical and life sciences industry is poised for a “flurry of deals” in the second half, according to PwC. read more By Ben Adams AstraZeneca launched the first ever COVID drug DTC for its prevention antibody, Evusheld, and it’s one of the most unusual and unique commercials you will see this year. read more By Andrea Park After rocketing to medtech stardom amid the COVID-19 pandemic, Cue Health seems to be drifting back down to Earth. read more By Kevin Dunleavy On Tuesday morning, Sanofi revealed two approvals from the European Commission—both for enzyme replacement treatments for rare diseases—that speak to CEO Paul Hudson’s mission to "play to win." read more By Angus Liu Inhibiting a protein could boost the efficacy of CAR-T cells by letting newly activated T cells preferentially differentiate toward long-lasting memory T cells rather than the short-living effector cells, scientists at St. Jude Children’s Research Hospital have shown. read more By Kevin Dunleavy AstraZeneca is pouring 65 million euros ($68.7 million) into two manufacturing sites in Ireland, which will increase drug substance production capabilities for AZ's rare disease unit Alexion. The funding comes nine months after AZ revealed a $360 million investment to build a next generation manufacturing site in Dublin. read more By Teresa Carey This week on "The Top Line," we discuss what FDA advisors want added to future COVID vaccine doses—and why. Also, experts predict an uptick in dealmaking, particularly for a few key companies. read more Resources Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities | 
